XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
SHAREHOLDERS' EQUITY (Detail Textuals)
$ / shares in Units, $ in Thousands
1 Months Ended 6 Months Ended
Apr. 14, 2020
shares
Oct. 10, 2018
USD ($)
$ / shares
Jun. 14, 2018
USD ($)
$ / shares
shares
Nov. 30, 2021
USD ($)
$ / shares
shares
Mar. 16, 2020
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2022
₪ / shares
Jun. 30, 2022
USD ($)
shares
Dec. 31, 2021
₪ / shares
shares
Ordinary shares, par value | ₪ / shares               ₪ 0.01   ₪ 0.01
Ordinary shares, shares authorized | shares                 200,000,000 200,000,000
Proceeds from warrant exercised           $ 0 $ 425      
Options granted | shares           1,497,500        
Stock options granted, exercise price, minimum | $ / shares           $ 1.9        
Stock options granted, exercise price, maximum | $ / shares           $ 5        
Vesting period           4 years        
Weighted average fair value of options granted during period | $ / shares           $ 1.94 $ 5.54      
Share based compensation stock options           $ 2,092 $ 1,805      
Unrecognized estimated compensation cost                 $ 11,614  
Period over which compensation expense will be recognized           2 years 10 months 6 days        
Total weighted average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share | shares           8,504,958 6,242,283      
Employee Stock Purchase Plan [Member]                    
Number of shares purchased for ESPP | shares           275,854        
Ordinary shares available for issuance | shares | shares                 324,146  
Share based compensation ESPP           $ 97 $ 111      
Warrant [Member]                    
Warrants purchase to ordinary shares | shares             89,557   0  
Proceeds from warrant exercised           0 $ 425      
Warrants purchase to ordinary shares remain outstanding | shares                 297,469  
Agreement [Member] | Registered direct offering [Member]                    
Value of shares issued     $ 19,767              
Issuance expenses     $ 1,233              
Ordinary shares, shares authorized | shares     5,316,457              
Warrants purchase to ordinary shares | shares     4,253,165              
Offering price per share | $ / shares     $ 3.95              
Exercise price of warrants | $ / shares     $ 4.74              
Expiration period of warrants     5 years              
Master Clinical Agreement [Member]                    
Proceeds from issuance of common stock   $ 2,424,243                
Issuance of shares, net, shares | shares       2,332,815            
Offering price per share | $ / shares   $ 4.95   $ 8.57333            
Equity investment   $ 12,000   $ 20,000            
Percentage of closing price   33.00%   33.00%            
Collaborative Arrangements [Member]                    
Issuance expenses           91        
Relative fair value of deferred participation                 $ 4,121  
Proceeds from equity investments           7,788        
Collaborative Arrangements Two [Member]                    
Issuance expenses           42        
Relative fair value of deferred participation                 $ 5,000  
Proceeds from equity investments           $ 14,958        
SVB Leerink LLC and Stifel, Nicolaus & Company [Member]                    
Issuance of shares, net, shares | shares         8,333,334 8,816,339        
Issuance expenses           $ 5,200        
Offering price per share | $ / shares         $ 9          
Proceeds from ordinary shares in offering           $ 74,147        
SVB Leerink LLC and Stifel, Nicolaus & Company [Member] | Underwriters [Member]                    
Issuance of shares, net, shares | shares 483,005                  
Offering price per share | $ / shares         $ 8.46